by Matthew Johnson | Aug 3, 2021 | PTAB News
By Matt Johnson – On July 6th and 7th, the USPTO made good on its promise to not wait for a confirmed director to begin Arthrex Director reviews, issuing its first denials of review requests. The full press release is below: USPTO issues first Director...
by Matthew Johnson | Jul 28, 2021 | Federal Circuit Appeal, Petitions
By Albert Liou – The Federal Circuit’s recent decision in Microsoft Corporation v. FG SRC, LLC, No. 2020-1928 (Fed. Cir. June 17, 2021), is a stark reminder that an IPR petitioner must always set forth its grounds in its petition with particularity. In the...
by Matthew Johnson | Jul 21, 2021 | PTAB News
By Matt Johnson – On July 20th, the PTAB provided additional clarifications regarding its views on Arthrex and how its interim procedures for requesting Director review will work for cases receiving Final Written Decisions on a going forward basis (i.e., not...
by Matthew Johnson | Jul 21, 2021 | PTAB News
The United States Supreme Court has delivered its decision in U.S. v. Arthrex, which determined whether appointments of administrative patent judges to the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) were constitutional. Jones Day’s Matt...
by Matthew Johnson | Jul 14, 2021 | Prior Art Issues
By Sue Gerber and Matt Johnson – This blog has previously discussed the Federal Circuit’s decision in Becton, Dickinson and Co. v. Baxter Corp. Englewood, — F.3d —, No. 2020-1937, 2021 WL 2176796 (Fed. Cir. May 28, 2021). See Telepharma Disconnect: ...
